A weekly e-journal by Art Epstein, OD, FAAO

#########

Volume 15, Number 32

Monday, August 10, 2015

#########

In this issue: (click heading to view article)
#########
######### Off the Cuff: DEWS II
#########
######### Circadian IOP Fluctuation and Disease Progression in Angle Closure Glaucoma
#########
######### Visual Performance of Single Vision and Multifocal Contact Lenses
#########
######### Human Color Perception Changes Between Seasons
#########
######### News & Notes
 

Click on the image for upcoming Conferences and Meetings.
http://www.facebook.com/pages/Optometric-Physician/256126944408439

 

Off the Cuff: DEWS II

The DEWS report, released in 2007, served as a pivotal document in delineating our understanding and management of dry eye and ocular surface disease. With the science and clinical practice literally exploding over the past few years, I am excited to report that the Tear Film and Ocular Surface Society (TFOS) has again assembled an international panel of leading scientists and clinicians for DEWS II, a DEWS sequel.

For this immense undertaking the number of experts involved was doubled and consists of some of the world’s brightest minds in every aspect of the tear film and ocular surface arena. I would quickly run out of space if I named just a fraction of the world-class people involved. Personally, I am both honored and humbled to serve on a DEWS II subcommittee.

Last week I was in Paris to attend the Tear Film subcommittee meeting. As many of you know I have long been immersed in tear film dynamics and I can tell you that the discussion was beyond mind expanding. It’s hard to contain my excitement for what DEWS II is likely to produce. Expect it to be a game changer in dry eye.

Editors Note: For those interested in dry eye and ocular surface disease, membership in TFOS is now free. You can sign up here.


 

Arthur B. Epstein, OD, FAAO
Chief Medical Editor
artepstein@optometricphysician.com

 

Want to share your perspective? Write to Dr. Epstein at artepstein@optometricphysician.com.

The views expressed in this editorial are solely those of the author and do not necessarily represent the opinions of the editorial board, Jobson Medical Information LLC (JMI), or any other entities or individuals.

 

 

 

Circadian IOP Fluctuation and Disease Progression in Angle Closure Glaucoma
 
 
This study evaluated the continuous circadian intraocular pressure (IOP) fluctuation using a contact lens sensor during normal daily activities, as well as the relationship between IOP fluctuation and disease progression in primary angle closure glaucoma (PACG) eyes.

Circadian IOP fluctuations were recorded by Sensimed Triggerfish sensors in 25 PACG eyes. The sensor output signals were transformed using B-spline smoothing and described by functional data analysis. Glaucoma progression was documented with serial changes in mean deviation (MD) and visual field index (VFI) in Humphrey automated perimetry and retinal nerve fiber layer (RNFL) thickness.

Statistically significant differences were found from 2200 to 2300 and from 0700 to 0800 in gradients of the IOP fluctuation curve, as well as from 2300 to 2400 and 0800 to 0900 in curvatures of the IOP fluctuation curves, between the progressive MD and stable MD groups. Significant gradient differences were also found from 1500 to 1600 and 0600 to 0800 between the progressive VFI and stable VFI groups, and from 2400 to 0100 and 0200 to 0300 between the progressive RNFL and stable RNFL groups.

Significant differences in circadian IOP fluctuation between progressive and stable PACG eyes were identified. Researchers concluded that large IOP fluctuations may be associated with disease progression in PACG eyes.


SOURCE: Tan S, Yu M, Baig N, et al. Circadian Intraocular Pressure Fluctuation and Disease Progression in Primary Angle Closure Glaucoma. Invest Ophthalmol Vis Sci. 2015;56(8):4994-5005.

 

Visual Performance of Single Vision and Multifocal Contact Lenses
 
 
Investigators assessed visual performance of single-vision and multifocal soft contact lenses. At baseline, 44 myopic participants (ages 18 to 35) were fitted bilaterally with a control lens (AirOptix Aqua). At four follow-up visits, a total of 16 study lenses (five single-vision, 11 multifocal lenses) were fitted contralaterally. After one hour of lens wear, participants rated (scale 1 to 10): vision clarity (distance, intermediate and near), magnitude of ghosting at distance, comfort during head movement and overall comfort. Distance high-contrast visual acuity (HCVA), central refraction and higher-order aberrations, and contact lens centration were measured.

For single-vision lenses, vision ratings were not significantly different from controls. The control outperformed Acuvue Oasys, Clariti Monthly and AirOptix Night and Day in HCVA. Most refraction and higher-order aberration measures were not different between lenses. The Night and Day lens showed the greatest differences compared to the control, i.e., C[4, 0] was more positive at distance (Δ=0.019μm) and near (Δ=0.028μm). For multifocal lenses, the majority of vision ratings (84%) were better with the control, including HCVA. Proclear Multifocal lenses showed greatest differences for M, C[3, -1] and C[4, 0] at distance and near, and were inferiorly de-centered.

Design differences between single-vision lenses had a small impact on visual performance. Investigators determined that lenses featuring multifocality decreased visual performance, in particular when power variations across the optic zone were large and/or the lens was significantly de-centered.


SOURCE: Fedtke C, Bakaraju RC, Ehrmann K, et al. Visual performance of single vision and multifocal contact lenses in non-presbyopic myopic eyes. Cont Lens Anterior Eye. 2015 Jul 27. [Epub ahead of print].

 

 

Human Color Perception Changes Between Seasons
 
 
Researchers reveal that humans identify four “unique hues”—blue, green, yellow and red—that do not appear to contain mixtures of other colors. Unique yellow (UY) is particularly interesting because it is stable across large populations: Participants reliably set a monochromatic light to a stereotypical wavelength. Individual variability in the ratio of L- and M-cones in the retina, and effects of aging impact unique green (UG) settings [1,2], but cannot predict the relatively small inter-individual differences in UY [2,3]. The stability of UY may arise because it is set by the environment rather than retinal physiology. Support for this idea comes from studies of long-term, artificial chromatic adaptation [4,5], but there is no evidence for this process in natural settings.

In a recent study, researchers measured 67 participants in York (England) in the winter and summer and found a significant seasonal change in UY settings. In comparison, Rayleigh color matches that would not be expected to exhibit environmentally driven changes were found to be constant. The seasonal shift in UY settings is consistent with a model that reweights L- and M-cone inputs into a perceptual opponent color channel after a small, seasonally driven change in mean L:M cone activity.

SOURCE: Welbourne LE, Morland AB, Wade AR. Human colour perception changes between seasons. Curr Biol. 2015;25(15):R646-7.

News & Notes
 
AOA PARTNERS WITH CDC FOR CONTACT LENS HEALTH WEEK. The American Optometric Association is encouraging eye care providers to remind teen patients heading back to school that proper contact lens wear and care promotes good vision and healthy eyes throughout the school year and life. The AOA is also spreading the word about the second annual CDC Contact Lens Health Week, as a partner of the efforts being held August 24-28.
ALLERGAN TO ACQUIRE OCULEVE DRY EYE DISEASE PROGRAMS. Allergan and Oculeve announced Allergan will acquire Oculeve for a $125 million upfront payment and commercialization milestone payments related to Oculeve's lead development program OD-01. The agreement also includes the acquisition of an earlier-stage dry eye device development program.



VITAL ART RECEIVES PATENT FOR HOME VISION MONITORING DEVICE. Vital Art and Science released news that the U.S. Patent Office granted a patent covering a novel technology of the company’s new mVT Service, an FDA-cleared prescription medical device that tracks changes caused by AMD and DR, enabling clinicians to catch disease progression early. The patent covers a handheld visual function testing component with a touchscreen display that communicates results to a database.
 
HEIDELBERG TO RELOCATE U.S. HEADQUARTERS. Heidelberg Engineering will relocate its U.S. headquarters from Carlsbad, Calif., to Franklin, Mass. The new East Coast location will integrate the technical support team operating out of Smithfield, R.I., and commercial expertise within the company’s U.S. organizations.
 



SHIRE ACQUIRES FORESIGHT BIOTHERAPEUTICS. Shire announced it acquired Foresight Biotherapeutics for $300 million, which includes global rights to FST-100 (topical ophthalmic drops combining 0.6% povidone iodine and 0.1% dexamethasone), a therapy in late-stage development for treatment of infectious conjunctivitis. If approved by regulatory agencies, FST-100 could become the first agent to treat both viral and bacterial conjunctivitis.
 
ALLEGRO ANNOUNCES POSITIVE LUMINATE PHASE II RESULTS. Allegro Ophthalmics announced the Phase II clinical trial of Luminate (ALG-1001) in patients with vitreomacular traction (VMT) or vitreomacular adhesion (VMA) met its primary endpoint. In the prospective, randomized, double-masked, placebo-controlled trial evaluating the safety/efficacy of Luminate intravitreal injections in 106 study subjects, 65% of eyes treated with a 3.2mg dose achieved release of VMT or VMA by day 90, compared to 9.7% in the placebo control group (p=0.0129).
 
   

 

 


Optometric Physician™ Editorial Board
 

Chief Medical Editor
Arthur B. Epstein, OD, FAAO

Journal Reviews
Shannon Steinhäuser, OD, FAAO


Contributing Editors
• Katherine M. Mastrota, MS, OD, FAAO
• Barry A. Weissman, OD, PhD, FAAO (Dip CL)

Editorial Board
• William Jones, OD, FAAO
• Alan G. Kabat, OD, FAAO
• Bruce Onofrey, RPh, OD, FAAO
• John Schachet, OD, FIOS
• Joseph Shovlin, OD, FAAO


 

 

Optometric Physician™ (OP) newsletter is owned and published by Dr. Arthur Epstein. It is distributed by the Review Group, a Division of Jobson Medical Information LLC (JMI), 11 Campus Boulevard, Newtown Square, PA 19073.

To change your email address, reply to this email. Write "change of address" in the subject line. Make sure to provide us with your old and new address.

To ensure delivery, please be sure to add Optometricphysician@jobsonmail.com to your address book or safe senders list.

Click here if you do not want to receive future emails from Optometric Physician.

HOW TO SUBMIT NEWS
E-mail optometricphysician@jobson.com or FAX your news to: 610.492.1039.

HOW TO ADVERTISE
For information on advertising in this e-mail newsletter or other creative advertising opportunities with Optometric Physician, please click here for advertising information.